Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program
04 janv. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
Kura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
01 déc. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification...
Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
15 nov. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will...
Kura Oncology Reports Third Quarter 2016 Financial Results
07 nov. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
04 nov. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the company’s...
Kura Oncology to Participate in Two Upcoming Investor Conferences
01 nov. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and...
Kura Oncology to Report Third Quarter 2016 Financial Results
31 oct. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the 9th European Scientific Oncology Conference
31 oct. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European...
Kura Oncology to Participate in the 2016 Aegis Growth Conference
14 sept. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth...
Kura Oncology Reports Second Quarter 2016 Financial Results
10 août 2016 16h03 HE
|
Kura Oncology, Inc.
Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at...